Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Raquel Izumi"'
Autor:
Anne-Sophie Rebstock, Mareike Wiedmann, Beatrix Stelte-Ludwig, Harvey Wong, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy, Hans-Georg Lerchen
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: The development of bioconjugates for the targeted delivery of anticancer agents is gaining momentum after recent success of antibody drug conjugates (ADCs) in the clinic. Smaller format conjugates may have several advantages including b
Externí odkaz:
https://doaj.org/article/48196de27ca84870b273d09b3f4c3f6d
Autor:
Jonathan J. Pinney, Sara K. Blick-Nitko, Andrea M. Baran, Derick R. Peterson, Hannah E. Whitehead, Raquel Izumi, Veerendra Munugalavadla, Karl R. Van DerMeid, Paul M. Barr, Clive S. Zent, Michael R. Elliott, Charles C. Chu
Publikováno v:
Haematologica, Vol 107, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/4bd1f29c68844e0bae492fc8f88bccbe
Autor:
Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps
Publikováno v:
Haematologica, Vol 106, Iss 9 (2021)
B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhib
Externí odkaz:
https://doaj.org/article/1f8e5a0d250d49f8bc29eb2cbf686fb6
Autor:
Bonnie K Harrington, Heather L Gardner, Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Kevin R Coombes, Todd Covey, Allard Kaptein, Michael Gulrajani, Bart Van Lith, Cecile Krejsa, Christopher C Coss, Duncan S Russell, Xiaoli Zhang, Bridget K Urie, Cheryl A London, John C Byrd, Amy J Johnson, William C Kisseberth
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159607 (2016)
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring cani
Externí odkaz:
https://doaj.org/article/885fb92964b3445a99b5a10f0adb8206
Autor:
Steven Sher, Ethan Whipp, Janek Walker, Pu Zhang, Larry Beaver, Katie Williams, Shelley Orwick, Janani Ravikrishnan, Brandi Walker, Elizabeth Perry, Charles Gregory, Matthew Purcell, Alexander Pan, Pearlly Yan, Lapo Alinari, Amy J. Johnson, Melanie M. Frigault, Joy M. Greer, Ahmed Hamdy, Raquel Izumi, Xiaokui Mo, Deepa Sampath, Jennifer Woyach, James Blachly, John C. Byrd, Rosa Lapalombella
Publikováno v:
Leukemia. 37:326-338
Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7a868428a2ac8c2b3894afc9dce8d9d
https://doi.org/10.1038/s41375-022-01758-z
https://doi.org/10.1038/s41375-022-01758-z
Autor:
John C. Byrd, Min-Hui Wang, Cheng Quah, Veerendra Munugalavadla, Raquel Izumi, Ahmed Hamdy, Melanie M. Frigault, Michael Gulrajani, Barbara L. Andersen, David M. Weiss, Gerard Lozanski, Mojgan Jianfar, Seema A. Bhat, Kerry A. Rogers, James S. Blachly, Jennifer A. Woyach
Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba6e8b6c08b1eaaf021847b37b47834a
https://doi.org/10.1158/2159-8290.c.6547811.v1
https://doi.org/10.1158/2159-8290.c.6547811.v1
Autor:
John C. Byrd, Min-Hui Wang, Cheng Quah, Veerendra Munugalavadla, Raquel Izumi, Ahmed Hamdy, Melanie M. Frigault, Michael Gulrajani, Barbara L. Andersen, David M. Weiss, Gerard Lozanski, Mojgan Jianfar, Seema A. Bhat, Kerry A. Rogers, James S. Blachly, Jennifer A. Woyach
Figure S1 shows immunoglobulin A, B, and M levels in treated patients over time Figure S2 shows investigator-assessed progression-free survival by CLL-IPI score and presence or absence of complex karyotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ecbd95eea50dde789f03387b686897
https://doi.org/10.1158/2159-8290.22535279.v1
https://doi.org/10.1158/2159-8290.22535279.v1
Autor:
Sarah E.M. Herman, Adrian Wiestner, Brian J. Lannutti, Roger Ulrich, Raquel Izumi, Nicholas Chiorazzi, Shih-Shih Chen, Todd Covey, Fanny Krantz, Eman L. Dadashian, Helena I. Mora-Jensen, Carsten U. Niemann
Supplementary methods and figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba9e963db2def1ccd6770542861e7c6d
https://doi.org/10.1158/1078-0432.22466763
https://doi.org/10.1158/1078-0432.22466763
Autor:
Victor Moreno, Harvey Wong, Raquel Izumi, Xin Huang, Ahmed M. Hamdy, Joy M. Greer, Melanie M. Frigault, Oliver Boix, Claudia Merz, Isabelle Genvresse, Ray Valencia, Daniel Morillo, Raul Cordoba, Grzegorz Nowakowski, Emerson Lim, Valentina Boni, Jennifer R. Diamond
Supplementary Table from First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::349103a7690abd8eb9a33fa70122d36c
https://doi.org/10.1158/1078-0432.22488152
https://doi.org/10.1158/1078-0432.22488152
Autor:
Victor Moreno, Harvey Wong, Raquel Izumi, Xin Huang, Ahmed M. Hamdy, Joy M. Greer, Melanie M. Frigault, Oliver Boix, Claudia Merz, Isabelle Genvresse, Ray Valencia, Daniel Morillo, Raul Cordoba, Grzegorz Nowakowski, Emerson Lim, Valentina Boni, Jennifer R. Diamond
Supplementary Figure from First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f2a6700edabfc66a9670dca8c598725
https://doi.org/10.1158/1078-0432.22488164.v1
https://doi.org/10.1158/1078-0432.22488164.v1